Imagen de Portada

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests?

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	C. Gaume, C. Moluçon Chabrot, P. Chabrot, A. Abergel
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests? Authors' reply
por: Maria Gabriela Fernandes Dezan, et al.
Publicado: (2024)

Editorial: Have you asked your patients about their difficulties in paying the medical costs of their treatment?
por: Abergel Armand, et al.
Publicado: (2024)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History
por: J. Ventre, et al.
Publicado: (2025)

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database
por: David Uihwan Lee, et al.
Publicado: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
por: C. Stephens
Publicado: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
por: Lisa Sandmann, et al.
Publicado: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index in predicting mortality and guiding prehabilitation
por: Sara J. Harris, et al.
Publicado: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
por: Wenjun Meng, et al.
Publicado: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index (DASI) in predicting mortality and guiding prehabilitation. Authors' reply
por: Matthew J. Armstrong, et al.
Publicado: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
por: Jian Wang, et al.
Publicado: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
por: Sung Won Chung, et al.
Publicado: (2024)

Editorial: Do we Need to Adapt GERD Metrics Based on the Population Being Evaluated? Authors' Reply
por: Walter W. Chan, et al.
Publicado: (2026)

Editorial: The future of managing drug induced liver injury
por: Amanda Nicoll
Publicado: (2024)

Characterisation of an outbreak of acute liver injury after ingestion of plant‐based food supplement
por: Gina Choi, et al.
Publicado: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question
por: Jenny Lövdahl, et al.
Publicado: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
por: Carolin V. Schneider, et al.
Publicado: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
por: Ivan Arcari, et al.
Publicado: (2024)

Review article: advances in the diagnosis and management of anorectal motility disorders
por: Dariush Shahsavari, et al.
Publicado: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
por: Shusuke Kumazaki, et al.
Publicado: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
por: Maria Ling Lundström, et al.
Publicado: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
por: Dipesh H. Vasant, et al.
Publicado: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
por: Richie Manikat, et al.
Publicado: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
por: Abdel‐Aziz Shaheen, et al.
Publicado: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
por: Stuart McPherson, et al.
Publicado: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
por: Mohamed I. Elsaid, et al.
Publicado: (2024)

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
por: Giammarco Mocci, et al.
Publicado: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
por: Basile Njei, et al.
Publicado: (2024)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
por: Xianhua Mao, et al.
Publicado: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
por: Manya Prasad, et al.
Publicado: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
por: Eunice X. X. Tan, et al.
Publicado: (2024)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
por: Victoria T. Kronsten, et al.
Publicado: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
por: Samer Gawrieh, et al.
Publicado: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
por: Richie Manikat, et al.
Publicado: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
por: Philip Vutien, et al.
Publicado: (2024)

Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients
por: Anna Fettiplace, et al.
Publicado: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
por: Min Wu, et al.
Publicado: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
por: Jannis Kountouras, et al.
Publicado: (2024)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
por: Mark C. C. Cheah, et al.
Publicado: (2025)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
por: Nobuharu Tamaki, et al.
Publicado: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
por: Nobuharu Tamaki, et al.
Publicado: (2024)